Drug Trial Radar · NCT05541510
Evaluating the Safety and Efficacy of AD17002 Intranasal Spray in Treating Participants With Mild to Moderate COVID-19
Last checked: Nov 19, 2026Latest source record: Sep 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
180
Actual
Start
Dec 1, 2022
Primary completion
Aug 5, 2024
Study completion Aug 25, 2024
Sponsor
- Lead sponsor
- Advagene Biopharma Co. Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Gadjah Mada University
- First posted
- Sep 15, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
AD17002 enhances nasal mucosal innate immunity and has met safety and efficacy endpoints in studies of nasal adjuvants or intranasal immunomodulators. This study aims to evaluate the safety and effectiveness of AD17002 in treating patients with mild to moderate COVID-19. All participants will be randomly divided into 1:1:1 groups and will receive standard treatment. Additionally, participants will be given either a placebo, 20, or 40 μg of AD17002 via intranasal delivery, and clinical progress will be compared.
Conditions
- COVID-19
Interventions
AD17002 + Formulation bufferBiological
Intranasal innate immune modulator
PlaceboBiological
Formulation buffer
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to disease improvementTime frame: [Day 1 to Day 29]
- Time to achieving the Patient Acceptable Symptom State (PASS)Time frame: [Day 1 to Day 29]
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
RSPI Sulianti Saroso
Kota Jkt Utara, DKI Jakarta, Indonesia
RSDC Wisma Atlit
Kota Jkt Utara, DKI Jakarta, Indonesia
RSA UGM
Yogyakarta, Special Region of Yogyakarta, Indonesia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.